505 related articles for article (PubMed ID: 31540705)
1. Aβ, Tau, and α-Synuclein aggregation and integrated role of PARK2 in the regulation and clearance of toxic peptides.
Kumar D; Kumar P
Neuropeptides; 2019 Dec; 78():101971. PubMed ID: 31540705
[TBL] [Abstract][Full Text] [Related]
2. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases.
Sengupta U; Kayed R
Prog Neurobiol; 2022 Jul; 214():102270. PubMed ID: 35447272
[TBL] [Abstract][Full Text] [Related]
3. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
4. Neuropathological and Biomarker Findings in Parkinson's Disease and Alzheimer's Disease: From Protein Aggregates to Synaptic Dysfunction.
Compta Y; Revesz T
J Parkinsons Dis; 2021; 11(1):107-121. PubMed ID: 33325398
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro.
Köppen J; Schulze A; Machner L; Wermann M; Eichentopf R; Guthardt M; Hähnel A; Klehm J; Kriegeskorte MC; Hartlage-Rübsamen M; Morawski M; von Hörsten S; Demuth HU; Roßner S; Schilling S
Molecules; 2020 Jan; 25(3):. PubMed ID: 32013170
[TBL] [Abstract][Full Text] [Related]
7. Endogenous Murine Amyloid-β Peptide Assembles into Aggregates in the Aged C57BL/6J Mouse Suggesting These Animals as a Model to Study Pathogenesis of Amyloid-β Plaque Formation.
Ahlemeyer B; Halupczok S; Rodenberg-Frank E; Valerius KP; Baumgart-Vogt E
J Alzheimers Dis; 2018; 61(4):1425-1450. PubMed ID: 29376876
[TBL] [Abstract][Full Text] [Related]
8. Associations Between APOE Variants, Tau and α-Synuclein.
Rodriguez-Vieitez E; Nielsen HM
Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
[TBL] [Abstract][Full Text] [Related]
9. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
Sierra M; Gelpi E; Martí MJ; Compta Y
Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
[TBL] [Abstract][Full Text] [Related]
10. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates.
Rostami J; Mothes T; Kolahdouzan M; Eriksson O; Moslem M; Bergström J; Ingelsson M; O'Callaghan P; Healy LM; Falk A; Erlandsson A
J Neuroinflammation; 2021 Jun; 18(1):124. PubMed ID: 34082772
[TBL] [Abstract][Full Text] [Related]
12. Parkin attenuates wild-type tau modification in the presence of beta-amyloid and alpha-synuclein.
Moussa CE
J Mol Neurosci; 2009 Jan; 37(1):25-36. PubMed ID: 18561034
[TBL] [Abstract][Full Text] [Related]
13. Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein.
Martinez-Valbuena I; Valenti-Azcarate R; Amat-Villegas I; Marcilla I; Marti-Andres G; Caballero MC; Riverol M; Tuñon MT; Fraser PE; Luquin MR
Acta Neuropathol Commun; 2021 Apr; 9(1):64. PubMed ID: 33832546
[TBL] [Abstract][Full Text] [Related]
14. The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics.
Noguchi-Shinohara M; Ono K
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373401
[TBL] [Abstract][Full Text] [Related]
15. [Expression of proteins related neurodegeneration in autopsy brains of the aged].
Zhu M; Meng X; Wang L; Hu Y; Zhang H; Han Z
Zhonghua Bing Li Xue Za Zhi; 2014 Oct; 43(10):651-6. PubMed ID: 25567589
[TBL] [Abstract][Full Text] [Related]
16. Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer's disease.
Shim KH; Kang MJ; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2022 Dec; 14(1):201. PubMed ID: 36587215
[TBL] [Abstract][Full Text] [Related]
17. I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.
Sieczkowski E; Milenkovic I; Venkataramani V; Giera R; Ströbel T; Höftberger R; Liberski PP; Auff E; Wirths O; Bayer TA; Kovacs GG
J Alzheimers Dis; 2015; 44(1):103-14. PubMed ID: 25182745
[TBL] [Abstract][Full Text] [Related]
18. Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
Dominguez-Meijide A; Vasili E; König A; Cima-Omori MS; Ibáñez de Opakua A; Leonov A; Ryazanov S; Zweckstetter M; Griesinger C; Outeiro TF
Sci Rep; 2020 Jul; 10(1):12827. PubMed ID: 32732936
[TBL] [Abstract][Full Text] [Related]
19. α-synuclein in the pathophysiology of Alzheimer's disease.
Twohig D; Nielsen HM
Mol Neurodegener; 2019 Jun; 14(1):23. PubMed ID: 31186026
[TBL] [Abstract][Full Text] [Related]
20. NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein.
Goedert M
Science; 2015 Aug; 349(6248):1255555. PubMed ID: 26250687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
